(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual revenue growth rate of 14.2% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.41%.
Neurocrine Biosciences's revenue in 2025 is $2,355,300,000.On average, 11 Wall Street analysts forecast NBIX's revenue for 2025 to be $263,937,170,745, with the lowest NBIX revenue forecast at $256,300,877,612, and the highest NBIX revenue forecast at $274,927,490,526. On average, 11 Wall Street analysts forecast NBIX's revenue for 2026 to be $302,946,773,905, with the lowest NBIX revenue forecast at $282,787,119,560, and the highest NBIX revenue forecast at $326,828,161,506.
In 2027, NBIX is forecast to generate $351,430,505,311 in revenue, with the lowest revenue forecast at $318,033,313,389 and the highest revenue forecast at $416,072,788,524.